Mesoblast Ltd SP ADR (MBLTY) 12.0800 $MBLTY
Global Degenerative Disc Disease Pipeline Review 2015 - 12 Companies & 15 Drug Profiles
M2 - Tue Oct 06, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rj7fth/degenerative_disc) has announced the addition of the "Degenerative Disc Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Degenerative Disc Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Degenerative Disc Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AnGes MG, Inc. - Biogenomics Limited - Bioheart, Inc. - Biopharm GmbH - BioRestorative Therapies, Inc. - Bone Therapeutics SA - Discgenics, Inc - ISTO Technologies, Inc. - K-Stemcell Co., Ltd. - Mesoblast Limited - TissueGene, Inc. - Yuhan Corporation Drug Profiles - AdipoCell - ALLOB - brtxDISC - CHND-1 - dibotermin alfa - MPC-25Osteo - NuQu - Peptides to Antagonize IL-1 Receptor for Dermatology, Musculoskeletal and CNS Disorders - Poly N-Acetyl Glucosamine Hydrogel - Recombinant Protein for Degenerative Disc Disease, Bone Fracture, Parkinson's Disease and Erectile Dysfunction - S-414114 - Stem Cell Therapy - Stem Cell Therapy for Degenerative Disc Disease - TG-D - YH-14618 For more information visit http://www.researchandmarkets.com/research/rj...ative_disc
Phase 2 Trial Results Show Mesoblast Cell Therapy Has Greatest Cardioprotective Effect In Patients With Advanced Heart Failure
GlobeNewswire - Tue Sep 29, 8:10PM CDT
Mesoblast Limited (ASX: MSB; USOTC:MBLTY) today announced that additional Phase 2 trial results of its lead product candidate for the treatment of chronic heart failure (CHF) were presented at the 19th Annual Scientific Meeting of the Heart Failure Society of America in National Harbor, MD, USA held from 26-29 September. The results showed that Mesoblast's mesenchymal precursor cell (MPC) therapy had the greatest cardioprotective effect in the subset of patients with more advanced heart failure.
Full Product Approval In Japan Received By Mesoblast Licensee
GlobeNewswire - Fri Sep 18, 12:23AM CDT
Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that its licensee JCR Pharmaceuticals Co. Ltd has received full approval from the Japanese Ministry of Health, Labour and Welfare for TEMCELL(R) HS Inj. (JR-031), an allogeneic mesenchymal stem cell product.
The New Age of Regenerative Medicine - Why Stem Cell Therapy?
M2 - Wed Sep 09, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/trw352/seg3d_the_new_age) has announced the addition of the "Seg3D The New Age of Regenerative Medicine" report to their offering. Cell therapy is the fastest growing segment of the Regenerative Medicine (RM) industry. It comprises both immune cell therapy and stem cell therapy; however, stem cell therapy makes up the largest part of this segment. The global cell therapy market is driven by the success of stem cell treatments in treating or curing life-threatening diseases such as cancer, heart disease, and neuro-muscular ailments among the aging population. This research study provides an overview of the regenerative medicine industry and an insight on successful stem cell therapy treatments. It also analyses marketed products, stem cell manufacturing and funding, and the collaborative partnerships in the regenerative medicine industry. Key Findings - Regenerative Medicine (RM) represents a new human-health paradigm with the potential to resolve unmet medical needs by addressing the underlying causes of diseases. - Globally, there are over companies focused on regenerative medicine. The United States has the most registered RM companies, followed by the United Kingdom, Germany and Japan. - Rapidly growing medical tourism, contract research outsourcing, and a rising population of patients with neurological and other chronic conditions are some of the factors driving the Asian stem cells market. Key Questions This Study Will Answer - What are some of the key developments impacting the regenerative medicine industry? - What are some of the key regulatory changes affecting the regenerative medicine industry? - How are investments and market consolidations progressing in Asia-Pacific? - What are some of the key participants making an impact in the regenerative medicine industry? Key Topics Covered: - Executive Summary - The New Age of Regenerative Medicine - An Overview - Stem Cell Manufacturing Facilities - Market Dynamics - Stem Cell Consumers - Future Trends - Regenerative Medicine Industry - Mergers, Acquisitions, and Partnership Assessment - Regenerative Medicine Industry - Funding Scenario - Overview of Regenerative Medicine in Asia-Pacific - Conclusion Companies Mentioned - MEDIPOST Co., Ltd. - Mesoblast Ltd. - Cellular Dynamics International (CDI) - Orthofix International - Capricor Therapeutics For more information visit http://www.researchandmarkets.com/research/tr...he_new_age
CAPR: 4.46 (-0.04), ICEL: 16.55 (+0.03)
Mesoblast Partner JCR Pharmaceuticals Receives Recommendation For Approval Of Mesenchymal Stem Cell Product In Japan
GlobeNewswire - Thu Sep 03, 7:44PM CDT
Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that the allogeneic mesenchymal stem cell-based regenerative medicine product JR-031, developed by Mesoblast's Japanese partner JCR Pharmaceuticals Co. Ltd., was recommended for approval on 2 September at a meeting organized by the Committee on Regenerative Medicine Products and Biological Technology of Pharmaceutical Affairs and Food Sanitation Council of the Japan Ministry of Health, Labour and Welfare. JCR said marketing approval of JR-031 is anticipated in the near future.
Type 2 Diabetes Trial Results Published In Diabetes Care
GlobeNewswire - Wed Jul 22, 6:17PM CDT
Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results of the Phase 2 trial of its intravenously-delivered Mesenchymal Precursor Cells (MPCs) for the treatment of type 2 diabetes have been published online ahead of full print in the peer-reviewed journal of the American Diabetes Association, Diabetes Care. The article is entitled "Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose Escalation Safety and Tolerability Pilot Study".
Low Back Pain Therapeutics Pipeline Review 2015 - 17 Companies & 19 Drug Profiles
M2 - Tue Jul 21, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qrggl2/low_back_pain) has announced the addition of the "Low Back Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Low Back Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aestus Therapeutics, Inc. - Astellas Pharma Inc. - Collegium Pharmaceutical, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Frontier Biotechnologies Co., Ltd - Grunenthal GmbH - Ipsen S.A. - MEDRx Co., Ltd. - Merck & Co., Inc. - Mesoblast Limited - Nektar Therapeutics - Pacira Pharmaceuticals, Inc. - Paladin Labs Inc. - Pfizer Inc. - Stayble Therapeutics - Teikoku Pharma USA, Inc. Drug Profiles - (acetaminophen tramadol hydrochloride) - (diclofenac sodium eperisone) - (etodolac lidocaine) - (etoricoxib tizanidine) - (oxycodone hydrochloride naltrexone) ER - AB-001 - abobotulinumtoxin A - ASP-7962 - Atx09-002 - bupivacaine hydrochloride - cebranopadol - Drug for Chronic Low Back Pain - duloxetine hydrochloride DR - eperisone SR - flurbiprofen sodium - MPC-06ID - NKTR-181 - oxycodone hydrochloride ER - PF-06372865 For more information visit http://www.researchandmarkets.com/research/qr..._back_pain
PFE: 33.24 (+0.15), MRK: 50.95 (-0.07), COLL: 20.67 (-0.19), LLY: 86.14 (+2.37), PCRX: 42.18 (+1.68), NKTR: 11.34 (+0.56), PTIE: 1.99 (+0.02)
Congestive Heart Failure Phase Trial Results Published In Circulation Research
GlobeNewswire - Tue Jul 14, 6:03PM CDT
Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that Phase 2 trial results of its cell therapy product candidate for the treatment of congestive heart failure (CHF) have been published in the latest edition of Circulation Research. The results were published as an "online first" article ahead of full print in this peer-reviewed, high-impact journal of the American Heart Association.
Chronic Heart Failure Pipeline Report 2015 - 16 Companies & 26 Drug Profiles
M2 - Fri Jul 10, 3:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z3fzgp/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AnGes MG, Inc. - ARCA biopharma, Inc. - Bayer AG - Bial - Portela & Ca, S.A. - Celyad - Jiangsu Hengrui Medicine Co., Ltd. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Mesoblast Limited - Novartis AG - Pfizer Inc. - PhaseBio Pharmaceuticals, Inc. - Sanofi - Stemedica Cell Technologies, Inc. - Zensun (Shanghai) Sci & Tech Co., Ltd. Drug Profiles - (sacubitril valsartan) - aliskiren fumarate - BAY-1067197 - beperminogene perplasmid - BIA-51058 - BR-5489 - C3BSCQR-1 - carvedilol phosphate ER - cenderitide - F-373280 - finerenone - furosemide - ivabradine - Mesenchymal Stem Cells - MPC-150IM - Neucardin - omecamtiv mecarbil - PB-1046 - Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - rivaroxaban - RNAi Gene Therapy to Inhibit STIM1 for Chronic Heart Failure and Atherosclerosis - SAR-296968 - serelaxin - sildenafil citrate - Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - vericiguat For more information visit http://www.researchandmarkets.com/research/z3...onic_heart
PFE: 33.24 (+0.15), AMGN: 149.59 (-0.31), NVS: 91.90 (-0.71), CYAD: 38.00 (+0.15)
Postive Trial Results Of Mesoblast Cell Therapy In Patients With Diabetes And Advanced Chronic Kidney Disease
GlobeNewswire - Mon Jun 08, 8:12PM CDT
Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results from the Company's Phase 2 trial in patients with diabetic nephropathy showed that a single infusion of its intravenously delivered allogeneic mesenchymal precursor cell (MPC) product candidate MPC-300-IV was safe, reduced damaging inflammation, and preserved or improved renal function over at least 24 weeks.
Global Diabetic Nephropathy Pipeline Review, H1 2015
M2 - Tue Jun 02, 7:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/frxw7k/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Bristol-Myers Squibb Company - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dimerix Bioscience Pty Ltd - Dong Wha Pharma Co., Ltd. - Eli Lilly and Company - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gentium S.p.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Glucox Biotech AB - GNI Group Ltd. - IMMD Inc. - Intercept Pharmaceuticals, Inc. - InterMune, Inc. - Inventiva SAS - Islet Sciences, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Mallinckrodt plc - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG For more information visit http://www.researchandmarkets.com/research/frxw7k/diabetic
NRX: 3.11 (-0.01), GALT: 2.61 (-0.10), LLY: 86.14 (+2.37), GSK: 40.22 (+0.06), BMY: 61.44 (+0.93), CTIC: 1.63 (-0.01), CNCE: 20.87 (+0.62), JNJ: 95.37 (+0.29), GILD: 100.65 (-0.16), AZN: 32.23 (-0.16), CCXI: 6.45 (+0.02), ICPT: 181.90 (-8.81), ABBV: 55.64 (-0.40)
Global Spinal Stenosis Pipeline Review 2015 - 5 Companies & 6 Drug Profiles
M2 - Wed May 20, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/68zlvw/spinal_stenosis) has announced the addition of the "Spinal Stenosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal Stenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Stenosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - LTT Bio-Pharma Co., Ltd. - Mesoblast Limited - Sucampo Pharmaceuticals, Inc. - Toray Industries, Inc. - Yungjin Pharm Ind. Co., Ltd. Drug Profiles - beraprost sodium SR - LT-0101 - MPC-25Osteo - SPI-017 - SPI-3608 - YLS-1501 For more information visit http://www.researchandmarkets.com/research/68...l_stenosis
SCMP: 18.19 (-1.21)
Diabetic Nephropathy Trial Results Selected For Late-Breaking Presentation At American Diabetes Association Annual Meeting
GlobeNewswire - Mon May 18, 4:39AM CDT
Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that Phase 2 trial results of its lead product candidate for the treatment of diabetic nephropathy have been selected for presentation at the late-breaking scientific sessions of the 75th American Diabetes Association (ADA) Scientific Sessions being held from June 5-9 in Boston, MA. The annual meeting is the largest diabetes meeting in the world, bringing together approximately 14,000 participants, including clinicians and researchers from 124 countries.
Global Ischemic Stroke Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w6cj3m/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Acorda Therapeutics, Inc. - Acticor Biotech - advanceCor GmbH - AGY Therapeutics, Inc. - Angion Biomedica Corp. - AstraZeneca PLC - Athersys, Inc. - Biogen Idec Inc. - BioTime, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - International Stem Cell Corporation - Laboratoires Pierre Fabre SA - Lumosa Therapeutics Co., Ltd. - MediaPharma s.r.l. - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neurotec Pharma SL - NeuroVive Pharmaceutical AB - Panacea Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - PhytoHealth Corporation - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. - Vicore Pharma AB - Virogenomics, Inc. For more information visit http://www.researchandmarkets.com/research/w6...mic_stroke
BIIB: 269.16 (-10.72), ACOR: 29.89 (-0.22), GSK: 40.22 (+0.06), AZN: 32.23 (-0.16), ATHX: 1.14 (-0.01), CUR: 1.33 (+0.03)
Mesoblast Cell Therapy Reduces Inflammation And Reverses Coronary Artery Dysfunction In Rheumatoid Arthritis Preclinical Study
GlobeNewswire - Tue May 12, 4:08AM CDT
Mesoblast Limited (ASX: MSB, USOTC:MBLTY) today announced publication of results in the May issue of the peer-reviewed journal PLOS One showing that its proprietary allogeneic mesenchymal precursor cells (MPCs) can reduce inflammation and reverse abnormal function of blood vessels, including the coronary arteries, in a previously published sheep model of rheumatoid arthritis. Since patients with rheumatoid arthritis have an approximately 50% higher risk of death from cardiovascular disease than the general population, these results suggest that the anti-inflammatory effect of MPC therapy may have an additional benefit in reducing cardiovascular risk associated with rheumatoid arthritis.
Repairs To The Heart: The Needle Or The Knife?
Keith Williams - at Seeking Alpha - Mon May 04, 11:37AM CDT
SSH: 2.66 (+0.07), NBS: 2.25 (-0.09), CLDN: 1.12 (+0.03)
Global Graft Versus Host Disease (GVHD) Pipeline Report 2015 - Analysis of 43 Companies & 66 Drug Profiles
M2 - Mon Apr 27, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjmb6v/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbGenomics International, Inc. - Adienne Pharma & Biotech - Alder Biopharmaceuticals Inc. - Alexion Pharmaceuticals, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Bellicum Pharmaceuticals, Inc. - Biogen Idec Inc. - Dr. Falk Pharma GmbH - Enlivex Therapeutics Ltd - Escape Therapeutics, Inc. - F. Hoffmann-La Roche Ltd. - Generon (Shanghai) Corporation Ltd. - Lycera Corp. - Mesoblast Limited - Millennium Pharmaceuticals, Inc. - MSM Protein Technologies, Inc. - Neopharm Ltd. - NeoStem, Inc. - Novartis AG - Omni Bio Pharmaceutical Inc. - Pharmacyclics, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - R-Tech Ueno, Ltd. - REGiMMUNE Corporation - Targazyme, Inc. - Therapix Biosciences Ltd - Tobira Therapeutics, Inc. - Xenikos B.V. For more information visit http://www.researchandmarkets.com/research/bj...ersus_host
BIIB: 269.16 (-10.72), PCYC: 261.25 (+1.70), PSTI: 1.84 (+0.06), NBS: 2.25 (-0.09), ALDR: 28.80 (-0.56), BLCM: 14.65 (+0.39), ALXN: 161.08 (-3.23), ATHX: 1.14 (-0.01), TBRA: 10.56 (-0.63), NVS: 91.90 (-0.71)
Global Bone Marrow Transplantation Pipeline Review 2015 - 12 Companies & 14 Drug Profiles
M2 - Mon Apr 27, 4:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dz5gfs/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Anchor Therapeutics, Inc. - Boryung Pharmaceutical Co., Ltd. - Cantex Pharmaceuticals, Inc. - Cellerant Therapeutics, Inc. - Cleveland BioLabs, Inc. - Compugen Ltd. - Mesoblast Limited - Pluristem Therapeutics Inc. - Proteonomix, Inc. - Spectrum Pharmaceuticals, Inc. - Taiga Biotechnologies, Inc. - Wellstat Therapeutics Corporation Drug Profiles - (filgrastim plerixafor) - ATI-2341 - BR-05001 - CBLB-612 - Cell Therapy for Bone Marrow Transplantation - CGEN-15001 - melphalan - MPC-CBE - PGX-100 - PLX-RAD - PN-951 - Protein for Bone Marrow Transplantation - romyelocel-L - Small Molecules to Inhibit Perforin for Bone Marrow Transplantation For more information visit http://www.researchandmarkets.com/research/dz...one_marrow
PSTI: 1.84 (+0.06), CGEN: 5.68 (-0.02), SPPI: 6.20 (+0.07), CBLI: 4.53 (+0.07)
Global Stem Cell Therapy Market Forecasts and Trends Report 2015-2020 - Cardiology, Oncology, Neurology, Diabetes, Orthopedics & Hematology
M2 - Thu Apr 23, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bvcjlr/stem_cell_therapy) has announced the addition of the "Stem Cell Therapy Global Market Forecast (2014-2020)" report to their offering. This report analyzes the global markets for Stem Cell Therapeutics. The report provides the standard and the tailored research methodology approach. The market overview offers in depth analysis for the regional and country level analysis, for instance North America (U.S., and Canada), Europe (Germany, France, Italy, U.K. and Spain), Asia-Pacific (China, Japan, India, South Korea and Rest of APAC) and Rest of the World (Middle East, Africa and Latin America). Annual estimations and forecasts are provided from the year 2012 to 2020 for each given segments and sub segments. Market data derived from the authenticated and reliable sources subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends. Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, other activities. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Analysis 4 Porters Five Force Analysis 5 Stem Cell Therapy Market by Applications 5.1 Cardiology 5.2 Oncology 5.3 Neurology 5.4 Diabetes 5.5 Orthopedics 5.6 Hematology 6 Stem Cell Therapy Market by Therapy Type 6.1 Autologous Stem Cell Therapy 6.2 Allogenous Stem Cell Therapy 6.3 Syngenous Stem Cell Therapy 7 Geographical Segmentation 8 Vendor Landscaping 9 Company Profiles - Aastrom Biosciences Inc. - Advanced Cell Technologies, Inc. - Celgene Corporation - Fibrocell Science, Inc. - Medipost - Mesoblast Ltd. - Pharmicell - Stem Cell Technologies For more information visit http://www.researchandmarkets.com/research/bv...ll_therapy
FCSC: 4.18 (+0.31), CELGZ: 1.74 (+0.04)
Orthopedics (Devices & Materials) - Global Trends, Estimates and Forecasts, 2013-2019
M2 - Tue Apr 21, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3mk33m/orthopedics) has announced the addition of the "Orthopedics (Devices & Materials) - Global Trends, Estimates and Forecasts, 2013-2019" report to their offering. Global Orthopedics (Devices and Material) market is estimated to reach US$57.2 billion by 2017. Devices types; Joints (Repair & Replacement) Industry market is worth US$40.2 billion by 2017, growing at a CAGR of 8.9% for the analysis period 2013-2019 respectively. The Americas region accounts for highest percentage approximately 56.6% (2016) of global share while Europe follows next with nearly 19.7% (2019) of the market. Asia-Pacific is the fastest growing region with a CAGR of 10.4% driving a market value of US$4.7 billion by 2016. By Material types; Orthopedics Biomaterials accounts for 48.3% of the market share and the rest is anticipated for Orthopedic Braces & Splints and Orthopedic Accessories. The report Orthopedics (Devices & Materials) - Global Trends, Estimates and Forecasts, 2013-2019' reviews the latest trends in orthopedics devices with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for healthcare sector investments. The study reveals profitable investment strategies for market start-ups, pharmaceutical/biotechnology companies, laboratories, Contract/Clinical/Commercial Research Organizations (CROs), government/academic organizations, consulting firms, database buyers and many more in preferred locations. The report primarily focuses on: - Emerging Market Trends - Advancements in the Technological Space - Market Demand of The Segments (By-Region) - Key Growth Areas and Market Size - Region-Wise Demand Factor - Key Competitors Edge - Investment Strategies Companies Mentioned: Partial List for Each region The Americas - Aesculap, Inc. - Amedica Corp. (Usa) - Arthrocare Corporation (Usa) - Biomet, Inc. (Usa) - Conmed Corp (Usa) - Corin Group Plc (Usa) - Depuy Synthess, Inc. (Usa) - Donjoy, Inc. (Usa) - Exactech, Inc. (Usa) - Globus Medical, Inc. (Usa) Europe - Aap Implantate Ag (Germany) - Metoxit Ag (France) - Arthro Kinetics Plc (Germany) - Biedermann Motech Gmbh & Co Kg (Germany) - Biotechni (France) - Dot Gmbh (Germany) - Eska Orthodynamics Gmbh (Germany) - Gruppo Bioimpianti S.R.L. (Italy) - Inion Oy (Finland) - Lima-Lto Medical Systems (Italy) - Mathys Ltd. Bettlach (Switzerland) - Medacta International Sa (Switzerland) - Memometal Technologies (United Kingdom) - Metoxit Ag (France) Asia-Pacific - Denyers International (Australia) - Mesoblast Limited (Australia) - Orthocare Pty Ltd (Australia) - Austofix Group Ltd (Australia) - Trauson Medical Instrument Co., Ltd (China) - Wuhan Dragonbio Orthopedic Products Co., Ltd. (China) - Canwell Medical Ltd (China) - Suzhou Ortho Instrument Co., Ltd. (China) - M J Surgical (India) Rest Of World - Hipokrat Inc. (Turkey) - Onur Medikal Ltd. (Turkey) For more information visit http://www.researchandmarkets.com/research/3m...rthopedics
GMED: 22.68 (+0.22), MDSY: 1.60 (unch), EXAC: 18.68 (-0.10), AMDA: 0.30 (-0.02)
Global Degenerative Disc Disease Pipeline Review 2015 - 12 Companies & 15 Drug Profiles
M2 - Tue Oct 06, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rj7fth/degenerative_disc) has announced the addition of the "Degenerative Disc Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Degenerative Disc Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Degenerative Disc Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AnGes MG, Inc. - Biogenomics Limited - Bioheart, Inc. - Biopharm GmbH - BioRestorative Therapies, Inc. - Bone Therapeutics SA - Discgenics, Inc - ISTO Technologies, Inc. - K-Stemcell Co., Ltd. - Mesoblast Limited - TissueGene, Inc. - Yuhan Corporation Drug Profiles - AdipoCell - ALLOB - brtxDISC - CHND-1 - dibotermin alfa - MPC-25Osteo - NuQu - Peptides to Antagonize IL-1 Receptor for Dermatology, Musculoskeletal and CNS Disorders - Poly N-Acetyl Glucosamine Hydrogel - Recombinant Protein for Degenerative Disc Disease, Bone Fracture, Parkinson's Disease and Erectile Dysfunction - S-414114 - Stem Cell Therapy - Stem Cell Therapy for Degenerative Disc Disease - TG-D - YH-14618 For more information visit http://www.researchandmarkets.com/research/rj...ative_disc
Phase 2 Trial Results Show Mesoblast Cell Therapy Has Greatest Cardioprotective Effect In Patients With Advanced Heart Failure
GlobeNewswire - Tue Sep 29, 8:10PM CDT
Mesoblast Limited (ASX: MSB; USOTC:MBLTY) today announced that additional Phase 2 trial results of its lead product candidate for the treatment of chronic heart failure (CHF) were presented at the 19th Annual Scientific Meeting of the Heart Failure Society of America in National Harbor, MD, USA held from 26-29 September. The results showed that Mesoblast's mesenchymal precursor cell (MPC) therapy had the greatest cardioprotective effect in the subset of patients with more advanced heart failure.
Full Product Approval In Japan Received By Mesoblast Licensee
GlobeNewswire - Fri Sep 18, 12:23AM CDT
Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that its licensee JCR Pharmaceuticals Co. Ltd has received full approval from the Japanese Ministry of Health, Labour and Welfare for TEMCELL(R) HS Inj. (JR-031), an allogeneic mesenchymal stem cell product.
The New Age of Regenerative Medicine - Why Stem Cell Therapy?
M2 - Wed Sep 09, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/trw352/seg3d_the_new_age) has announced the addition of the "Seg3D The New Age of Regenerative Medicine" report to their offering. Cell therapy is the fastest growing segment of the Regenerative Medicine (RM) industry. It comprises both immune cell therapy and stem cell therapy; however, stem cell therapy makes up the largest part of this segment. The global cell therapy market is driven by the success of stem cell treatments in treating or curing life-threatening diseases such as cancer, heart disease, and neuro-muscular ailments among the aging population. This research study provides an overview of the regenerative medicine industry and an insight on successful stem cell therapy treatments. It also analyses marketed products, stem cell manufacturing and funding, and the collaborative partnerships in the regenerative medicine industry. Key Findings - Regenerative Medicine (RM) represents a new human-health paradigm with the potential to resolve unmet medical needs by addressing the underlying causes of diseases. - Globally, there are over companies focused on regenerative medicine. The United States has the most registered RM companies, followed by the United Kingdom, Germany and Japan. - Rapidly growing medical tourism, contract research outsourcing, and a rising population of patients with neurological and other chronic conditions are some of the factors driving the Asian stem cells market. Key Questions This Study Will Answer - What are some of the key developments impacting the regenerative medicine industry? - What are some of the key regulatory changes affecting the regenerative medicine industry? - How are investments and market consolidations progressing in Asia-Pacific? - What are some of the key participants making an impact in the regenerative medicine industry? Key Topics Covered: - Executive Summary - The New Age of Regenerative Medicine - An Overview - Stem Cell Manufacturing Facilities - Market Dynamics - Stem Cell Consumers - Future Trends - Regenerative Medicine Industry - Mergers, Acquisitions, and Partnership Assessment - Regenerative Medicine Industry - Funding Scenario - Overview of Regenerative Medicine in Asia-Pacific - Conclusion Companies Mentioned - MEDIPOST Co., Ltd. - Mesoblast Ltd. - Cellular Dynamics International (CDI) - Orthofix International - Capricor Therapeutics For more information visit http://www.researchandmarkets.com/research/tr...he_new_age
CAPR: 4.46 (-0.04), ICEL: 16.55 (+0.03)
Mesoblast Partner JCR Pharmaceuticals Receives Recommendation For Approval Of Mesenchymal Stem Cell Product In Japan
GlobeNewswire - Thu Sep 03, 7:44PM CDT
Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that the allogeneic mesenchymal stem cell-based regenerative medicine product JR-031, developed by Mesoblast's Japanese partner JCR Pharmaceuticals Co. Ltd., was recommended for approval on 2 September at a meeting organized by the Committee on Regenerative Medicine Products and Biological Technology of Pharmaceutical Affairs and Food Sanitation Council of the Japan Ministry of Health, Labour and Welfare. JCR said marketing approval of JR-031 is anticipated in the near future.
Type 2 Diabetes Trial Results Published In Diabetes Care
GlobeNewswire - Wed Jul 22, 6:17PM CDT
Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results of the Phase 2 trial of its intravenously-delivered Mesenchymal Precursor Cells (MPCs) for the treatment of type 2 diabetes have been published online ahead of full print in the peer-reviewed journal of the American Diabetes Association, Diabetes Care. The article is entitled "Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose Escalation Safety and Tolerability Pilot Study".
Low Back Pain Therapeutics Pipeline Review 2015 - 17 Companies & 19 Drug Profiles
M2 - Tue Jul 21, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qrggl2/low_back_pain) has announced the addition of the "Low Back Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Low Back Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aestus Therapeutics, Inc. - Astellas Pharma Inc. - Collegium Pharmaceutical, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Frontier Biotechnologies Co., Ltd - Grunenthal GmbH - Ipsen S.A. - MEDRx Co., Ltd. - Merck & Co., Inc. - Mesoblast Limited - Nektar Therapeutics - Pacira Pharmaceuticals, Inc. - Paladin Labs Inc. - Pfizer Inc. - Stayble Therapeutics - Teikoku Pharma USA, Inc. Drug Profiles - (acetaminophen tramadol hydrochloride) - (diclofenac sodium eperisone) - (etodolac lidocaine) - (etoricoxib tizanidine) - (oxycodone hydrochloride naltrexone) ER - AB-001 - abobotulinumtoxin A - ASP-7962 - Atx09-002 - bupivacaine hydrochloride - cebranopadol - Drug for Chronic Low Back Pain - duloxetine hydrochloride DR - eperisone SR - flurbiprofen sodium - MPC-06ID - NKTR-181 - oxycodone hydrochloride ER - PF-06372865 For more information visit http://www.researchandmarkets.com/research/qr..._back_pain
PFE: 33.24 (+0.15), MRK: 50.95 (-0.07), COLL: 20.67 (-0.19), LLY: 86.14 (+2.37), PCRX: 42.18 (+1.68), NKTR: 11.34 (+0.56), PTIE: 1.99 (+0.02)
Congestive Heart Failure Phase Trial Results Published In Circulation Research
GlobeNewswire - Tue Jul 14, 6:03PM CDT
Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that Phase 2 trial results of its cell therapy product candidate for the treatment of congestive heart failure (CHF) have been published in the latest edition of Circulation Research. The results were published as an "online first" article ahead of full print in this peer-reviewed, high-impact journal of the American Heart Association.
Chronic Heart Failure Pipeline Report 2015 - 16 Companies & 26 Drug Profiles
M2 - Fri Jul 10, 3:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z3fzgp/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AnGes MG, Inc. - ARCA biopharma, Inc. - Bayer AG - Bial - Portela & Ca, S.A. - Celyad - Jiangsu Hengrui Medicine Co., Ltd. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Mesoblast Limited - Novartis AG - Pfizer Inc. - PhaseBio Pharmaceuticals, Inc. - Sanofi - Stemedica Cell Technologies, Inc. - Zensun (Shanghai) Sci & Tech Co., Ltd. Drug Profiles - (sacubitril valsartan) - aliskiren fumarate - BAY-1067197 - beperminogene perplasmid - BIA-51058 - BR-5489 - C3BSCQR-1 - carvedilol phosphate ER - cenderitide - F-373280 - finerenone - furosemide - ivabradine - Mesenchymal Stem Cells - MPC-150IM - Neucardin - omecamtiv mecarbil - PB-1046 - Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - rivaroxaban - RNAi Gene Therapy to Inhibit STIM1 for Chronic Heart Failure and Atherosclerosis - SAR-296968 - serelaxin - sildenafil citrate - Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - vericiguat For more information visit http://www.researchandmarkets.com/research/z3...onic_heart
PFE: 33.24 (+0.15), AMGN: 149.59 (-0.31), NVS: 91.90 (-0.71), CYAD: 38.00 (+0.15)
Postive Trial Results Of Mesoblast Cell Therapy In Patients With Diabetes And Advanced Chronic Kidney Disease
GlobeNewswire - Mon Jun 08, 8:12PM CDT
Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results from the Company's Phase 2 trial in patients with diabetic nephropathy showed that a single infusion of its intravenously delivered allogeneic mesenchymal precursor cell (MPC) product candidate MPC-300-IV was safe, reduced damaging inflammation, and preserved or improved renal function over at least 24 weeks.
Global Diabetic Nephropathy Pipeline Review, H1 2015
M2 - Tue Jun 02, 7:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/frxw7k/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Bristol-Myers Squibb Company - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dimerix Bioscience Pty Ltd - Dong Wha Pharma Co., Ltd. - Eli Lilly and Company - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gentium S.p.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Glucox Biotech AB - GNI Group Ltd. - IMMD Inc. - Intercept Pharmaceuticals, Inc. - InterMune, Inc. - Inventiva SAS - Islet Sciences, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Mallinckrodt plc - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG For more information visit http://www.researchandmarkets.com/research/frxw7k/diabetic
NRX: 3.11 (-0.01), GALT: 2.61 (-0.10), LLY: 86.14 (+2.37), GSK: 40.22 (+0.06), BMY: 61.44 (+0.93), CTIC: 1.63 (-0.01), CNCE: 20.87 (+0.62), JNJ: 95.37 (+0.29), GILD: 100.65 (-0.16), AZN: 32.23 (-0.16), CCXI: 6.45 (+0.02), ICPT: 181.90 (-8.81), ABBV: 55.64 (-0.40)
Global Spinal Stenosis Pipeline Review 2015 - 5 Companies & 6 Drug Profiles
M2 - Wed May 20, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/68zlvw/spinal_stenosis) has announced the addition of the "Spinal Stenosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal Stenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Stenosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - LTT Bio-Pharma Co., Ltd. - Mesoblast Limited - Sucampo Pharmaceuticals, Inc. - Toray Industries, Inc. - Yungjin Pharm Ind. Co., Ltd. Drug Profiles - beraprost sodium SR - LT-0101 - MPC-25Osteo - SPI-017 - SPI-3608 - YLS-1501 For more information visit http://www.researchandmarkets.com/research/68...l_stenosis
SCMP: 18.19 (-1.21)
Diabetic Nephropathy Trial Results Selected For Late-Breaking Presentation At American Diabetes Association Annual Meeting
GlobeNewswire - Mon May 18, 4:39AM CDT
Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that Phase 2 trial results of its lead product candidate for the treatment of diabetic nephropathy have been selected for presentation at the late-breaking scientific sessions of the 75th American Diabetes Association (ADA) Scientific Sessions being held from June 5-9 in Boston, MA. The annual meeting is the largest diabetes meeting in the world, bringing together approximately 14,000 participants, including clinicians and researchers from 124 countries.
Global Ischemic Stroke Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w6cj3m/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Acorda Therapeutics, Inc. - Acticor Biotech - advanceCor GmbH - AGY Therapeutics, Inc. - Angion Biomedica Corp. - AstraZeneca PLC - Athersys, Inc. - Biogen Idec Inc. - BioTime, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - International Stem Cell Corporation - Laboratoires Pierre Fabre SA - Lumosa Therapeutics Co., Ltd. - MediaPharma s.r.l. - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neurotec Pharma SL - NeuroVive Pharmaceutical AB - Panacea Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - PhytoHealth Corporation - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. - Vicore Pharma AB - Virogenomics, Inc. For more information visit http://www.researchandmarkets.com/research/w6...mic_stroke
BIIB: 269.16 (-10.72), ACOR: 29.89 (-0.22), GSK: 40.22 (+0.06), AZN: 32.23 (-0.16), ATHX: 1.14 (-0.01), CUR: 1.33 (+0.03)
Mesoblast Cell Therapy Reduces Inflammation And Reverses Coronary Artery Dysfunction In Rheumatoid Arthritis Preclinical Study
GlobeNewswire - Tue May 12, 4:08AM CDT
Mesoblast Limited (ASX: MSB, USOTC:MBLTY) today announced publication of results in the May issue of the peer-reviewed journal PLOS One showing that its proprietary allogeneic mesenchymal precursor cells (MPCs) can reduce inflammation and reverse abnormal function of blood vessels, including the coronary arteries, in a previously published sheep model of rheumatoid arthritis. Since patients with rheumatoid arthritis have an approximately 50% higher risk of death from cardiovascular disease than the general population, these results suggest that the anti-inflammatory effect of MPC therapy may have an additional benefit in reducing cardiovascular risk associated with rheumatoid arthritis.
Repairs To The Heart: The Needle Or The Knife?
Keith Williams - at Seeking Alpha - Mon May 04, 11:37AM CDT
SSH: 2.66 (+0.07), NBS: 2.25 (-0.09), CLDN: 1.12 (+0.03)
Global Graft Versus Host Disease (GVHD) Pipeline Report 2015 - Analysis of 43 Companies & 66 Drug Profiles
M2 - Mon Apr 27, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjmb6v/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbGenomics International, Inc. - Adienne Pharma & Biotech - Alder Biopharmaceuticals Inc. - Alexion Pharmaceuticals, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Bellicum Pharmaceuticals, Inc. - Biogen Idec Inc. - Dr. Falk Pharma GmbH - Enlivex Therapeutics Ltd - Escape Therapeutics, Inc. - F. Hoffmann-La Roche Ltd. - Generon (Shanghai) Corporation Ltd. - Lycera Corp. - Mesoblast Limited - Millennium Pharmaceuticals, Inc. - MSM Protein Technologies, Inc. - Neopharm Ltd. - NeoStem, Inc. - Novartis AG - Omni Bio Pharmaceutical Inc. - Pharmacyclics, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - R-Tech Ueno, Ltd. - REGiMMUNE Corporation - Targazyme, Inc. - Therapix Biosciences Ltd - Tobira Therapeutics, Inc. - Xenikos B.V. For more information visit http://www.researchandmarkets.com/research/bj...ersus_host
BIIB: 269.16 (-10.72), PCYC: 261.25 (+1.70), PSTI: 1.84 (+0.06), NBS: 2.25 (-0.09), ALDR: 28.80 (-0.56), BLCM: 14.65 (+0.39), ALXN: 161.08 (-3.23), ATHX: 1.14 (-0.01), TBRA: 10.56 (-0.63), NVS: 91.90 (-0.71)
Global Bone Marrow Transplantation Pipeline Review 2015 - 12 Companies & 14 Drug Profiles
M2 - Mon Apr 27, 4:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dz5gfs/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Anchor Therapeutics, Inc. - Boryung Pharmaceutical Co., Ltd. - Cantex Pharmaceuticals, Inc. - Cellerant Therapeutics, Inc. - Cleveland BioLabs, Inc. - Compugen Ltd. - Mesoblast Limited - Pluristem Therapeutics Inc. - Proteonomix, Inc. - Spectrum Pharmaceuticals, Inc. - Taiga Biotechnologies, Inc. - Wellstat Therapeutics Corporation Drug Profiles - (filgrastim plerixafor) - ATI-2341 - BR-05001 - CBLB-612 - Cell Therapy for Bone Marrow Transplantation - CGEN-15001 - melphalan - MPC-CBE - PGX-100 - PLX-RAD - PN-951 - Protein for Bone Marrow Transplantation - romyelocel-L - Small Molecules to Inhibit Perforin for Bone Marrow Transplantation For more information visit http://www.researchandmarkets.com/research/dz...one_marrow
PSTI: 1.84 (+0.06), CGEN: 5.68 (-0.02), SPPI: 6.20 (+0.07), CBLI: 4.53 (+0.07)
Global Stem Cell Therapy Market Forecasts and Trends Report 2015-2020 - Cardiology, Oncology, Neurology, Diabetes, Orthopedics & Hematology
M2 - Thu Apr 23, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bvcjlr/stem_cell_therapy) has announced the addition of the "Stem Cell Therapy Global Market Forecast (2014-2020)" report to their offering. This report analyzes the global markets for Stem Cell Therapeutics. The report provides the standard and the tailored research methodology approach. The market overview offers in depth analysis for the regional and country level analysis, for instance North America (U.S., and Canada), Europe (Germany, France, Italy, U.K. and Spain), Asia-Pacific (China, Japan, India, South Korea and Rest of APAC) and Rest of the World (Middle East, Africa and Latin America). Annual estimations and forecasts are provided from the year 2012 to 2020 for each given segments and sub segments. Market data derived from the authenticated and reliable sources subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends. Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, other activities. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Analysis 4 Porters Five Force Analysis 5 Stem Cell Therapy Market by Applications 5.1 Cardiology 5.2 Oncology 5.3 Neurology 5.4 Diabetes 5.5 Orthopedics 5.6 Hematology 6 Stem Cell Therapy Market by Therapy Type 6.1 Autologous Stem Cell Therapy 6.2 Allogenous Stem Cell Therapy 6.3 Syngenous Stem Cell Therapy 7 Geographical Segmentation 8 Vendor Landscaping 9 Company Profiles - Aastrom Biosciences Inc. - Advanced Cell Technologies, Inc. - Celgene Corporation - Fibrocell Science, Inc. - Medipost - Mesoblast Ltd. - Pharmicell - Stem Cell Technologies For more information visit http://www.researchandmarkets.com/research/bv...ll_therapy
FCSC: 4.18 (+0.31), CELGZ: 1.74 (+0.04)
Orthopedics (Devices & Materials) - Global Trends, Estimates and Forecasts, 2013-2019
M2 - Tue Apr 21, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3mk33m/orthopedics) has announced the addition of the "Orthopedics (Devices & Materials) - Global Trends, Estimates and Forecasts, 2013-2019" report to their offering. Global Orthopedics (Devices and Material) market is estimated to reach US$57.2 billion by 2017. Devices types; Joints (Repair & Replacement) Industry market is worth US$40.2 billion by 2017, growing at a CAGR of 8.9% for the analysis period 2013-2019 respectively. The Americas region accounts for highest percentage approximately 56.6% (2016) of global share while Europe follows next with nearly 19.7% (2019) of the market. Asia-Pacific is the fastest growing region with a CAGR of 10.4% driving a market value of US$4.7 billion by 2016. By Material types; Orthopedics Biomaterials accounts for 48.3% of the market share and the rest is anticipated for Orthopedic Braces & Splints and Orthopedic Accessories. The report Orthopedics (Devices & Materials) - Global Trends, Estimates and Forecasts, 2013-2019' reviews the latest trends in orthopedics devices with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for healthcare sector investments. The study reveals profitable investment strategies for market start-ups, pharmaceutical/biotechnology companies, laboratories, Contract/Clinical/Commercial Research Organizations (CROs), government/academic organizations, consulting firms, database buyers and many more in preferred locations. The report primarily focuses on: - Emerging Market Trends - Advancements in the Technological Space - Market Demand of The Segments (By-Region) - Key Growth Areas and Market Size - Region-Wise Demand Factor - Key Competitors Edge - Investment Strategies Companies Mentioned: Partial List for Each region The Americas - Aesculap, Inc. - Amedica Corp. (Usa) - Arthrocare Corporation (Usa) - Biomet, Inc. (Usa) - Conmed Corp (Usa) - Corin Group Plc (Usa) - Depuy Synthess, Inc. (Usa) - Donjoy, Inc. (Usa) - Exactech, Inc. (Usa) - Globus Medical, Inc. (Usa) Europe - Aap Implantate Ag (Germany) - Metoxit Ag (France) - Arthro Kinetics Plc (Germany) - Biedermann Motech Gmbh & Co Kg (Germany) - Biotechni (France) - Dot Gmbh (Germany) - Eska Orthodynamics Gmbh (Germany) - Gruppo Bioimpianti S.R.L. (Italy) - Inion Oy (Finland) - Lima-Lto Medical Systems (Italy) - Mathys Ltd. Bettlach (Switzerland) - Medacta International Sa (Switzerland) - Memometal Technologies (United Kingdom) - Metoxit Ag (France) Asia-Pacific - Denyers International (Australia) - Mesoblast Limited (Australia) - Orthocare Pty Ltd (Australia) - Austofix Group Ltd (Australia) - Trauson Medical Instrument Co., Ltd (China) - Wuhan Dragonbio Orthopedic Products Co., Ltd. (China) - Canwell Medical Ltd (China) - Suzhou Ortho Instrument Co., Ltd. (China) - M J Surgical (India) Rest Of World - Hipokrat Inc. (Turkey) - Onur Medikal Ltd. (Turkey) For more information visit http://www.researchandmarkets.com/research/3m...rthopedics
GMED: 22.68 (+0.22), MDSY: 1.60 (unch), EXAC: 18.68 (-0.10), AMDA: 0.30 (-0.02)
